DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES
- None.
- None.
Insights
The granting of a new patent to Daxor Corporation for a clinical guidance system in blood volume management represents a significant step forward in the medical technology landscape. This innovation is poised to enhance the precision of fluid management interventions, a critical component in treating conditions like heart failure, critical care, hypertension, surgical blood loss and sepsis. These conditions are not only prevalent but also represent a substantial portion of healthcare costs.
From a research perspective, the uniqueness of the patented system lies in its algorithmic approach, integrating blood volume metrics with clinical measures. This integration could lead to improved patient outcomes by enabling more accurate and timely interventions. The proprietary nature of this technology could also result in a competitive edge for Daxor in the medical device market, as it may become a standard tool in fluid management, potentially leading to increased market share and revenue growth.
However, the adoption of such advanced systems depends on clinician training, the integration with existing hospital protocols and the demonstration of cost-effectiveness through clinical trials. The long-term impact on Daxor's business will be contingent upon these factors, as well as the ability to maintain their technological lead through continuous innovation and protection of intellectual property.
The issuance of this patent is not merely a technical milestone; it has profound economic implications for the healthcare industry. Fluid management is a common challenge across various high-cost medical conditions and the patented system by Daxor could potentially reduce the financial burden on healthcare systems by improving treatment efficiency and reducing hospital readmission rates.
By streamlining the decision-making process in fluid management with its algorithmic treatment system, Daxor may contribute to lowering the overall cost of care. This is particularly relevant in the context of value-based care models, where healthcare providers are incentivized to deliver high-quality care at lower costs. If Daxor's system can demonstrate cost savings while maintaining or improving patient outcomes, it could see rapid adoption.
Nevertheless, the economic benefits hinge on the system's ability to scale and integrate into diverse healthcare settings. The upfront costs of adoption, potential disruption to established workflows and the learning curve associated with new technologies are factors that could affect the rate of adoption and therefore the economic impact of this patent.
The strategic implications of the new patent for Daxor's blood volume measurement technology are multifaceted. On one hand, the patent strengthens Daxor's intellectual property portfolio, which can be a critical factor in attracting investment and partnerships. On the other hand, it positions the company at the forefront of innovation in a niche but important segment of the medical device market.
Market analysis suggests that the demand for precision fluid management is on the rise, driven by an aging population and the increasing prevalence of chronic diseases. Daxor's patented system could meet this demand by offering a differentiated product that improves clinical outcomes. This could translate into increased adoption rates among hospitals and clinics, provided that the system aligns with the current trend toward data-driven and personalized medicine.
It is important to monitor how Daxor capitalizes on this patent in terms of product development, marketing strategies and sales execution. The company's ability to convert this patent into successful commercial products will be a key determinant of its impact on the stock market and its financial performance.
Patent Covers Systems and Methods For Algorithmic Treatment Across a Spectrum of Conditions
Oak Ridge, TN, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that the United States Patent and Trademark Office has issued the company a second patent (U.S. Patent No. 11,862,311 B2), safeguarding a distinctive clinical guidance system for blood volume management. This system utilizes unique blood volume metrics and related clinical measures to create support guidance for fluid management interventions.
"Our new patented system makes fluid management decisions significantly easier – driving better outcomes and empowering clinicians at all levels to make more effective treatment decisions. We are thrilled to add this patent to our family of patents covering key innovations in the use of blood volume analysis for precision fluid treatment guidance,” said Jonathan Feldschuh, Daxor’s Chief Scientific Officer. “This patent protects Daxor’s cutting-edge technology for the use in the most common and costly conditions including heart failure, critical care, hypertension, surgical blood loss and sepsis.”
“Given the cost and complexity of healthcare, intelligent computer-assisted support tools are a major focus for hospital systems to improve outcomes and reduce costs. At Daxor, our mission is to advance healthcare by enabling optimal fluid management, equipping physicians with the tools for more effective diagnosis and treatment. Our proprietary technology, protected by numerous patents, ensures a distinct advantage as we introduce next-generation products to the market, advancing this mission,” said Michael Feldschuh, Daxor’s CEO and President.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What is the latest patent received by Daxor Corporation?
What conditions does the patented system target?
Who is Daxor Corporation's Chief Scientific Officer?
Who is Daxor Corporation's CEO and President?
What is Daxor Corporation's ticker symbol?
